Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease

The ALZpath difference

ALZpath provides diagnostic tools and expertise in Alzheimer’s disease.  We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.

Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification
brain

A timely and accessible diagnosis

Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:

  • Simple
  • Accessible
  • Timely
  • Cost-effective
  • Less invasive

pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.

Recent ALZpath News

ALZpath Partners with Roche to Provide pTau217 Antibody for Alzheimer's Diagnostic Blood Test

June 10, 2024

ALZpath has announced a strategic license agreement with Roche for use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer’s disease diagnostic blood test that will be offered by Roche. The Roche pTau217 test was recently granted Breakthrough Device designation by the FDA and will be commercialized as part of an ongoing collaboration between Roche and Eli Lilly.

ALZpath CEO Dr. Venkat Shastri Recognized in TIME100 Health List for Advancing Alzheimer’s Disease Diagnosis

May 2, 2024

Dr. Venkat Shastri, Co-Founder and CEO of ALZpath, has been named to the TIME100 Health list for his pioneering work in developing a proprietary diagnostic tool for early Alzheimer’s disease detection. The recognition highlights the impact of ALZpath’s innovative pTau217 blood-based test in revolutionizing Alzheimer’s diagnosis and potentially transforming patient care.

ALZpath Announces Strategic Partnership with Alamar Biosciences

February 29, 2024

ALZpath has partnered with Alamar Biosciences to integrate ALZpath pTau217 antibodies into Alamar’s NULISA™ platform. Through integrating ALZpath’s pTau217 antibody into its NULISAqpcr™ pTau-217 Assay, as well as in their multiplexed NULISAseq™ CNS Disease Panel 120. Together, we are driving breakthroughs in understanding neurodegenerative diseases. This collaboration marks a significant milestone in advancing novel tools for neurodegenerative disease research.

ALZpath pTau217 Measured in Dried Blood Spots as Effective Method for Remote Settings

January 29, 2024

In a recent study published in Alzheimer’s & Dementia, researchers present groundbreaking findings on the precision of pTau217 biomarker measurements in dried blood spots. This important study highlights the potential to extend ALZpath pTau217 diagnostic capabilities to remote settings, offering simplified sampling conditions and storage logistics using dried blood spots.